Lincoln Pharmaceuticals Limited

BSE:531633 Stock Report

Market Cap: ₹16.1b

Lincoln Pharmaceuticals Past Earnings Performance

Past criteria checks 3/6

Lincoln Pharmaceuticals has been growing earnings at an average annual rate of 13.1%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 9.5% per year. Lincoln Pharmaceuticals's return on equity is 15.1%, and it has net margins of 16.2%.

Key information

13.1%

Earnings growth rate

13.1%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate9.5%
Return on equity15.1%
Net Margin16.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Lincoln Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:531633 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 245,9749661,1290
30 Jun 245,9229801,0540
31 Mar 245,8059331,0740
31 Dec 235,5058731,0660
30 Sep 235,3788081,0360
30 Jun 235,2257699670
31 Mar 235,1037299810
31 Dec 225,0047141,0500
30 Sep 224,8666749480
30 Jun 224,7346677410
31 Mar 224,7216948520
31 Dec 214,4917098520
30 Sep 214,4406688190
30 Jun 214,4266476480
31 Mar 214,2426237570
31 Dec 204,2315867100
30 Sep 204,0685607150
30 Jun 203,9355405630
31 Mar 203,8655147560
31 Dec 193,8735107060
30 Sep 193,7334927110
30 Jun 193,6324535360
31 Mar 193,6614876670
31 Dec 183,5424706750
30 Sep 183,2384956790
30 Jun 183,1094585350
31 Mar 183,6063466620
31 Dec 174,4632815500
30 Sep 174,3642315070
30 Jun 174,0632064970
31 Mar 173,6032815060
31 Dec 163,6503015220
30 Sep 163,9953014900
30 Jun 164,2452813320
31 Mar 164,0022373710
31 Dec 153,5042195520
30 Sep 153,1001805240
30 Jun 152,9261834940
31 Mar 152,6611502350
31 Dec 142,5451354200
30 Sep 142,4201424220
30 Jun 142,1811061840
31 Mar 142,1071074280

Quality Earnings: 531633 has a large one-off gain of ₹224.9M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 531633's current net profit margins (16.2%) are higher than last year (15%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 531633's earnings have grown by 13.1% per year over the past 5 years.

Accelerating Growth: 531633's earnings growth over the past year (19.5%) exceeds its 5-year average (13.1% per year).

Earnings vs Industry: 531633 earnings growth over the past year (19.5%) did not outperform the Pharmaceuticals industry 20.5%.

Return on Equity

High ROE: 531633's Return on Equity (15.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 19:11
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lincoln Pharmaceuticals Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kameswari V. S. ChavaliFirstCall Research